# XFOR catalysts: X4 Pharmaceuticals, Inc PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/xfor/catalysts

> X4 Pharmaceuticals, Inc (XFOR) has 8 upcoming catalysts. The next is the XOLREMDI® (mavorixafor) primary completion, September 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | X4 Pharmaceuticals, Inc |
| Ticker | XFOR (Nasdaq) |
| SEC CIK | 1501697 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/xfor |

## Cash runway

Cash $185.8M as of 2026-09-30; quarterly burn $20.2M; about 27.6 months of runway at that rate (XBRL company facts, accession 0001501697-26-000089).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 31, 2023 | [XOLREMDI® (mavorixafor) NDA/BLA acceptance](https://sec-api.dev/pdufa/mavorixafor) | XFOR | people aged 12 years and older with WHIM syndrome | completed | "For the year ended December 31, 2023, a $5.0 million milestone was incurred and paid upon the FDA's acceptance of the Company's NDA seeking approval of oral, once-daily mavorixafor in the treatment of people aged 12 years and older with WHIM syndrome." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1501697/000162828025014805/xfor-20241231.htm)) |
| April 29, 2024 | [XOLREMDI® (mavorixafor) FDA approval](https://sec-api.dev/pdufa/mavorixafor) | XFOR | CN, we expect | completed, approved | "On April 29, 2024, the Company announced that the U.S. Food and Drug Administration ("FDA") approved the Company's New Drug Application ("NDA") for mavorixafor, which is being marketed in the U.S. under the trade name XOLREMDI®, for use as an oral, once-daily therapy in patients 12 years of age and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis), to increase the number of circulating mature neutrophils and lymphocytes." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1501697/000162828025039327/xfor-20250630.htm)) |
| September 30, 2024 | [X4 Pharmaceuticals, Inc FDA approval](https://sec-api.dev/companies/xfor/catalysts) | XFOR |  | completed, approved | "During the nine months ended September 30, 2024, a $7.0 million regulatory milestone payment was made after receipt of FDA approval of the Company's NDA on April 26, 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1501697/000162828024047445/xfor-20240930.htm)) |
| November 13, 2024 | [X4 Pharmaceuticals, Inc earnings report](https://sec-api.dev/companies/xfor/catalysts) | XFOR |  | completed | "X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501697/000162828024047406/a991pressreleasedatednovem.htm)) |
| December 31, 2024 | [XOLREMDI® (mavorixafor) FDA approval](https://sec-api.dev/pdufa/mavorixafor) | XFOR |  | completed, approved | "For the year ended December 31, 2024, a $7.0 million regulatory milestone payment was incurred and paid after receipt of FDA approval of the Company's NDA on April 26, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1501697/000162828025014805/xfor-20241231.htm)) |
| March 25, 2025 | [X4 Pharmaceuticals, Inc earnings report](https://sec-api.dev/companies/xfor/catalysts) | XFOR |  | completed | "BOSTON, Mass., March 25, 2025 - X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the fourth quarter and full year ended December 31, 2024, and highlighted key 2024 and recent events and expected upcoming milestones." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501697/000162828025014601/a991earningsreleasedatedma.htm)) |
| May 1, 2025 | [X4 Pharmaceuticals, Inc earnings report](https://sec-api.dev/companies/xfor/catalysts) | XFOR |  | completed | "X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501697/000162828025021304/a991earningsreleasedatedma.htm)) |
| November 5, 2025 | [X4 Pharmaceuticals, Inc earnings report](https://sec-api.dev/companies/xfor/catalysts) | XFOR |  | completed | "X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501697/000150169725000041/ex-991pressreleasenovember.htm)) |
| December 23, 2025 | [XOLREMDI® (mavorixafor) primary completion](https://sec-api.dev/pdufa/mavorixafor) | XFOR | WHIM Syndrome | completed | "NCT03995108 (Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-23 (ACTUAL); Lead Sponsor X4 Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03995108)) |
| 2H 2026 | [XOLREMDI® (mavorixafor) topline data readout](https://sec-api.dev/pdufa/mavorixafor) | XFOR |  | scheduled | "Top-line 4WARD data expected in 2H 2026 NEXT VALUE DRIVERS: LARGER INDICATION OF CHRONIC NEUTROPENIA & TARGETED EUROPEAN WHIM APPROVAL" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501697/000162828025021304/ex_992xx4updatedinvestor.htm)) |
| September 2027 | [XOLREMDI® (mavorixafor) primary completion](https://sec-api.dev/pdufa/mavorixafor) | XFOR | Neutropenia | scheduled | "NCT06056297 (A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor X4 Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06056297)) |
| Sep to Dec 2027 | [XOLREMDI® (mavorixafor) topline data readout](https://sec-api.dev/pdufa/mavorixafor) | XFOR | Neutropenia | scheduled | "NCT06056297 (A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor X4 Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06056297)) |
| 1H 2028 | [X4 Pharmaceuticals, Inc topline data readout](https://sec-api.dev/companies/xfor/catalysts) | XFOR |  | scheduled | "- Expect Completion of Enrollment in Phase 3 4WARD trial by Year-End 2026 and Topline Data in H1 2028 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501697/000150169726000081/ex991pressreleasedatedocto.htm)) |
| 1H 2028 | [X4 Pharmaceuticals, Inc topline data readout](https://sec-api.dev/companies/xfor/catalysts) | XFOR |  | scheduled | "- Expect Completion of Enrollment by Year-End 2026 and Topline Data in H1 2028 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501697/000150169726000072/a991_x4typecoutcome.htm)) |
| Q1 2028 | [XOLREMDI® (mavorixafor) topline data readout](https://sec-api.dev/pdufa/mavorixafor) | XFOR |  | scheduled | "Top-line pivotal Phase 3 study in Primary Chronic Neutropenia data expected in Q1 2028" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501697/000150169726000084/ex991_x4presentation.htm)) |
| late 2028 | [XOLREMDI® (mavorixafor) NDA/BLA submission](https://sec-api.dev/pdufa/mavorixafor) | XFOR |  | scheduled | "•With a strengthened cash runway to the end of 2028, X4 is now expected to be able to complete the 4WARD trial, file a potential sNDA for the chronic neutropenia indication, and, if successful, launch mavorixafor in this new indication by the end of 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501697/000150169725000041/ex-991pressreleasenovember.htm)) |
| Jan to Apr 2029 | [XOLREMDI® (mavorixafor) topline data readout](https://sec-api.dev/pdufa/mavorixafor) | XFOR |  | scheduled | "NCT07902830 (A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-01-30 (ESTIMATED); Lead Sponsor X4 Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07902830)) |
| January 2029 | [XOLREMDI® (mavorixafor) primary completion](https://sec-api.dev/pdufa/mavorixafor) | XFOR |  | scheduled | "NCT07902830 (A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-01-30 (ESTIMATED); Lead Sponsor X4 Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07902830)) |

## Drugs

- [XOLREMDI® (mavorixafor)](https://sec-api.dev/pdufa/mavorixafor): cn, we expect, people aged 12 years and older with whim syndrome, Neutropenia, WHIM Syndrome, Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/xfor/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "XFOR catalysts: X4 Pharmaceuticals, Inc PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/xfor/catalysts

```bibtex
@misc{secapidev_companies_xfor_catalysts_20261116,
  title        = {XFOR catalysts: X4 Pharmaceuticals, Inc PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/xfor/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_xfor_catalysts_20261116","title":"XFOR catalysts: X4 Pharmaceuticals, Inc PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/xfor/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
